11q23 chromosome translocations occur in 5 ± 10% of acute lymphocytic leukemias (ALL) and in 46% of acute myeloid leukemias (AML) in both children and adults (Lee et al., 1999; Homan et al., 2000) . Remarkably, the majority of infant (up to 1 year of age) acute leukemias and therapy-related leukemias are associated with 11q23 abnormalities (Pui et al., 1991a,b; Hunger et al., 1993; Chen et al., 1993; Cimino et al., 1995) . These alterations uniformly carry poor prognosis, despite aggressive treatments or application of bone marrow transplantation. The leukemic cells from patients with ALL and t(4 : 11) are characterized by progenitor B-cell marker pro®le of CD10 . A high percentage of these leukemias display some myeloid features, such as the CD15 or CDw65 antigens (Pui et al., 1991a; Griesinger et al., 1994) , suggesting that the cell of origin is an early progenitor with the potential for both lymphoid and myelomonocytic dierentiation. 11q23 chromosome translocations involve an unusually large number of loci (430). The most common partner locus is 4q21, participating in the t(4 : 11). This aberration is nearly always associated with acute lymphocytic leukemia. The second most frequent partner is 9p21, involved in the t(9 : 11). This translocation is usually associated with acute myeloid leukemia. Other, moderately encountered partners are positioned at 19p13, 6q27 and 10p12 (reviewed in DiMartino and Cleary, 1999) .
Recombination between the ALL-1 gene and partner genes underlie most 11q23 abnormalities (Gu et al., 1992; Tkachuk et al., 1992) . The fused genes encode chimeric proteins composed of the N-terminal *1400 residues of ALL-1 linked to the C-terminal segments of the partner proteins. Experiments with mouse models demonstrated that the chimeric proteins directly trigger leukemia (Corral et al., 1996; Slany et al., 1998) . Around 20 partner genes have been already cloned (reviewed in DiMartino and Cleary, 1999) and while a few, like AF-9 and ENL or AF-10 and AF-17, are very similar, the rest appear a diverse lot. Recent studies of other leukemias involving fusion proteins have suggested that the role of the partner proteins PML and ETO, within the leukemogenic chimeric proteins PML-RAR and ETO-AML1, respectively is to confer homooligomerization (Minucci et al., 2000; Lin 2nd Evans, 2000) . These ®ndings raise the possibility that homooligomerization is also provided by ALL-1 partner proteins. The presence of a leucine zipper oligomerization motif within AF-10 and AF-17 and the capacity of the oligomerizable b-galactosidase to function as a partner to ALL-1 (Dobson et al., 2000) , are consistent with this possibility.
ALL-1 is the human homologue of Drosophila trithorax. Like the latter it functions during development, in maintaining temporal and spatial expression of homeobox (Hox) genes (Yu et al., 1995; Hanson et al., 1999) . Analysis of ®broblasts of ALL-1-de®cient mouse embryos indicated loss of all or most expression of the HoxA and the HoxC clusters (Hanson et al., 1999) . These results in conjunction with studies demonstrating physical association between the TRITHORAX protein and a chromatin element positioned adjacent to the Drosophila Hox homologue ubx ., Rozovskaia et al., 1999 , suggest direct regulation of HoxA and HoxC transcription by ALL-1. Further, in analogy to the TRITHORAX protein which binds Hox as well as many other non-Hox genes (presumably targets) on Drosophila polytene chromosomes (Rozovskaia et al., 1999) , ALL-1 is thought to regulate both Hox and non-Hox loci.
The eect of ALL-1 fusion proteins on transcription of speci®c genes has not been studied yet. It is conceivable that these proteins reach the same target genes of normal ALL-1 and bring about abnormal overexpression or repression. To approach this issue and begin to identify potential targets of ALL-1 fusion proteins we applied the genome-wide screening methodology (described in Brown and Botstein, 1999) ) but without the chromosome translocation. An Incyte/Synteni Uni-GEMV slide array, containing around 9700 human cDNA clones, 60% of them encoding known genes, was hybridized simultaneously to dierentially-labeled cDNA probes derived from the two types of ALLs. For each gene on the array, the ratio of the hybridization signals re¯ected the relative abundance of its transcript within the two types of tumors. Among the genes found most overexpressed in tumors with the chromosome abnormality (the entire analysis will be published elsewhere), we identi®ed three which were previously associated with normal and/or malignant hematopoiesis. These included AC133 (Yin et al., 1997; BuÈ hring et al., 1999) , Meis1 (Moscow et al., 1995; Nakamura et al., 1996b; Kroon et al., 1998; Lawrence et al., 1999) , and HoxA9 (Nakamura et al., 1996b; Kroon et al., 1998; Lawrence et al., 1999).
These genes, together with HoxA7 and HoxA10, also implicated in leukemia (Nakamura et al., 1996b; Afonja et al., 1997; Thorsteindottier et al., 1997) and HoxA5, HoxC8 and HoxC10, were now examined by RT ± PCR for their expression in individual primary acute leukemias with or without ALL-1 rearrangements.
With the exception of one infant with t(4 : 11) all tumors were from patients enrolled in the GIMEMA ALL and AML clinical trials. The tumors comprised 14 ALLs with the t(4 : 11), ®ve AMLs with the t(9 : 11), single AMLs with the t(11 : 19), or t(10 : 11) or with ALL-1 partial duplication (Schichman et al., 1995) . Leukemias without rearrangements of ALL-1 consisted of the major classes of ALLs: 10 PrePreB ALLs with a CD19 + CD10 7 phenotype, eight common PreB CD10 + ALLs, three Philadelphia chromosome positive ALLs, nine T ALLs (tested only for Meis1 and HoxA9 expression). Also examined were ®ve M5 AMLs. Examples of the RT ± PCR analysis are shown in Figure 1 . Thus, all samples of ALL with t(4 : 11) produced strong signals for Meis1, whereas only a single sample of PrePreB ALL was positive in this assay (Figure 1a, top) . Very similar results were obtained for HoxA9 (Figure 1a , middle). Eight AMLs with ALL-1 rearrangements were strongly positive for both HoxA9 and Meis1 (Figure 1a , bottom). The results of the entire analysis are shown in Table 1 (not included are nine T ALLs, three of which were strongly positive for both Meis1 and HoxA9). Among the eight genes examined, expression of Meis1 and HoxA9 showed the best correlation with ALL-1 rearrangements -13/14 of ALLs with t(4 : 11) and 8/8 of AMLs with t(9 : 11) or t(11 : 19) or t(10 : 11) or ALL-1 partial duplication. Most control ALLs did not express the two genes. In contrast, 4/5 of control AMLs contained RNAs of Meis1 and HoxA9. Expression of the latter two in most AMLs, and repression of the two genes in ALLs was recently reported . AC133 was found transcribed in 13/14 of ALLs with t(4 : 11) and in 2/10 of PrePreB ALLs. The correlation with ALL-1 rearrangements did not extend to AMLs, where in 4/8 of the relevant tumors AC133 RNA could not be detected. HoxA10 was expressed in 10/12 ALLs with t(4 : 11) and in 8/8 AMLs with ALL-1 alterations (although to lower levels in three tumors). On the other side, HoxA10 was also transcribed in the majority of PrePreB ALLs. For the other Hox genes examined ± HoxA5, HoxA7, HoxC8 and HoxC10 ± no clear correlation with ALL-1 alterations was found. It is of interest that these four Hox genes as well as HoxA10, but not HoxA9 and Meis1, were expressed in the majority of the progenitor PrePreB tumors. This further suggests speci®city in the regulation of the last two genes.
To quantify more accurately the amounts of the genes' transcripts in the leukemic cells, we used the LightCycler TM (Roche) for real-time monitoring of DNA ampli®cation reactions. In this methodology the kinetics of¯uorescent accumulation (resulting from its binding to duplex DNA) during PCR are directly Oncogene Meis1 and HoxA9 in leukemias with the t(4:11) abnormality T Rozovskaia et al related to the starting number of template copies (Higuchi et al., 1993; Wittwer et al., 1997) . Applying this technique, RNAs from leukemias with t(4 : 11) and PrePreB ALLs were quanti®ed for Meis1, HoxA9 and AC133. An example of this analysis for HoxA9 is shown in Figure 1b . Identical aliquots of RNAs (containing equal amounts of b-actin) from ALLs with t(4 : 11) were reverse-transcribed and PCR ampli®ed to generate the plots depicted in Figure 1b . Crossing points (cycle number) into the noise-band line were used to calculate the initial concentrations of HoxA9 amplicon DNAs according to a standard curve generated with known amounts of the amplicon DNA (inset). The entire analysis indicated that the concentrations of HoxA9, Meis1 and AC133 in samples designated as high expressors (Table 1) The studies reported here constitute an initial attempt to identify genes whose expression is correlated with ALL-1 rearrangements. Such genes could correspond to direct or indirect targets for ALL-1 fusion proteins. Alternatively, the mode of transcription of these genes could simply re¯ect the type of progenitor cells which make up the leukemic clone. Genome-wide DNA microarray screen pointed out Meis1, HoxA9 and AC133 to be overexpressed in PrePreB ALLs with t(4 : 11), compared to other PrePreB ALLs. These genes and several other Hox genes, were examined by RT ± PCR for expression in primary acute leukemias. Meis1 and HoxA9 showed the best correlation with ALL-1 rearrangements, being expressed in 21/22 tumors with such aberrations. The two genes were only sporadically transcribed in other types of ALL, including PrePreB ALLs, but were expressed in most AMLs lacking ALL- Figure 1 Semi-quantitative (a) and quantitative (b) RT ± PCR analysis. Most patients analysed throughout this investigation were adults, with the exception of one infant with t(4 : 11). Leukemic cells (490% blasts) from bone marrow or peripheral blood were isolated on Ficoll gradient, and RNA was isolated utilizing Tri Reagent (Sigma) or the acid guanidinium thiocyanate-phenol-chloroform method. For hybridization to DNA microarrays (results not shown), the two cDNA probes were synthesized from 50 mg aliquots of t(4 : 11) and PrePreB leukemic cell RNAs using 18-mer oligo-dT primer. Cy3-dCTP and Cy5-dCTP (Amersham) were used to dierentially label the two probes and were incorporated during reverse transcription. Hybridization, scanning and quantitation of the results were performed as previously described (Schena et al., 1996) . In (a), Meis1 and HoxA9 were examined in primary PrePreB CD10
7 ALLs with and without the t(4 : 11) abnormality (top, middle), and in primary AMLs with ALL-1 rearrangements (bottom). The AMLs included the aberrations t(9 : 11) (lanes 1 ± 5), t(11 : 19) (lane 6), t(10 : 11) (lane 7) and ALL-1 partial duplication (lane 8). Samples of 1 mg RNA were reverse-transcribed; 5% of it were PCR ampli®ed, and portions of 10% of the products were electrophoretically analysed. Size markers (bp) are shown on the right. In (b), 1 mg aliquots of RNA of PrePreB ALLs with t(4 : 11) were reverse-transcribed and 2% portions were PCR ampli®ed in 20 ml reaction volume in the LightCycler TM instrument (Roche), according to protocols of the manufacturer (¯uorescent dye was SYBR Green I). At the end of the ampli®cation, products were assessed for validity and uniformity by melting curve analysis and by gel electrophoresis. Standard curve for HoxA9 amplicon DNA is shown in the inset. Primers used for semi-quantitative and quantitative PCR throughout this investigation were: Meis1, 5'-CAAGTTATACCCAACCCCAG-3' (forward), 5'-GGTCCAGAGTAGATGCCAAG-3' (backward); HoxA9, 5'-AAAAATCTACCTGTTCCTGAC-3' (forward 1), 5'-CTATCTTCCACAATCACAATGGG-3' (backward 1), 5'-CCCAGCAGCCAACTGGCTTCATGCGC-3' (forward 2), 5'-CACTCGTCTTTTGCTCGGTCTTTG-3' (backward 2); HoxA5, 5'-GCGCTACCAGACCCTGGAGCTGG-3' (forward), 5'-GGCCATGCTCATGCTTTTCAGCTTA-3' (backward); HoxA7, 5'-CCGGACAA-CAAATCACAGGTCA-3' (forward), 5'-CCCCGTAGCCGCTTCTCTGTGAG-3' (backward); AC133, 5'-GCTCAGAACTTCATCA-CAAAC-3' (forward 1), 5'-ACATCATCGTACACGTCCTC-3' (backward 1), 5'-AACAATTCACCAGCAACGAG-3' (forward 2), 5'-CACAGAAAGACATCAACAGCAG-3' (backward 2); HoxA10, 5'-GATCCGGTTTTCTCGATTCA-3' (forward), 5'-ACACTGGAGCTG-GAGAAGGA-3' (backward 1), 5'-GCAAAGAGTGGTCGGAAGAA-3' (backward 2); HoxC8, 5'-GGCATCTCCAACTCAGGCTA-3' (forward), 5'-ACAGTCGGGATATTGCACCA-3' (backward); HoxC10, 5'-AGAGCGGAAGGAAGAAGAGG-3' (forward), 5'-GATCC-GATTCTCTCGGTTCA-3' (backward); b actin, 5'-TACAGGAAGTCCCTTGCCAT-3' (forward), 5'-CTGGTCTCAAGTCAGTGTAC-3' (backward) 1 alterations. HoxA10 was expressed in similar fashion as Meis1 and HoxA9, but was also transcribed in most PrePreB ALLs. The three genes, but in particular Meis1 and HoxA9, were previously implicated in murine and human acute myeloid leukemia. Thus, HoxA9 was frequently found co-activated with Meis1 in spontaneous AML of BXH-2 mice. The activation was due to simultaneous retroviral integrations into the two loci (Nakamura et al., 1996b) . Further, forced overexpression of the two genes, but not of each alone, in murine bone marrow cells rapidly induced AML when transplanted into syngenic mice (Kroon et al., 1998) . Also, in human AML with the t(7 : 11) chromosome translocation, HoxA9 is fused to NUP98 to encode a chimeric protein (Nakamura et al., 1996a; Borrow et al., 1996) . Moreover, HoxA9 and Meis1 were found transcribed in the majority of human acute myeloid leukemias . Importantly, overexpression of HoxA9 in human AMLs was correlated with treatment failure (Golub et al., 1999) . Finally, HoxA10 is also expressed in many human AMLs and its forced expression in mouse bone marrow cells induced AML at high frequency though with long latency (Thorsteindottier et al., 1997) . Recent studies have shown that the apparent cooperation between HoxA9 and Meis1 is due to the formation of DNA-binding triple complexes containing these proteins as well as PBX (Shen et al., 1999; Schnabel et al., 2000) . Complexes containing HoxA10, Meis1 and PBX were also identi®ed (Shen et al., 1999) .
The expression of HoxA9 and Meis1 in the majority of ALLs with t(4 : 11) contrasts with the general repression of the two genes in other classes of acute lymphocytic leukemia. This, combined with the evidence that HoxA9 is activated (presumably directly) by normal ALL-1 (Hanson et al., 1999) suggests that in tumors with t(4 : 11) the two genes are activated by ALL-1/AF-4. By extension, the two genes will be also activated by other ALL-1 fusion proteins. On the other hand, the activation of Meis1 and HoxA9 in many acute myeloid leukemias lacking of ALL-1 rearrangements Golub et al., 1999 ; this study), together with the well-known myeloid involvement in ALLs with t(4 : 11) (see above; additional references in Johansson et al., 1998) , raises the possibility that ALL-1/AF-4 itself might not be directly associated with transcription of Meis1 and HoxA9. Notwithstanding this present uncertainty, the consistent coexpression of this highly oncogenic gene pair in leukemias with ALL-1 alterations, strongly suggests that the two genes have a role in pathogenesis of these malignancies and as such could constitute targets for therapy. The incentive to develop rational therapy directed against Meis1 and HoxA9 derives from both the correlation between HoxA9 overexpression and treatment failure in AMLs and from the general poor prognosis for patients with the t(4 : 11) or with other ALL-1 rearrangements. 
